Prescription Digital Therapeutics – Addressing Unmet Needs Among Patients With Mental Health Conditions

Arwen Podesta, MD, defines what prescription digital therapeutics (PDTs) are, describes how they differ from nonprescription digital health tools, and details the FDA review process for PDTs.

Arwen Podesta, MD, details the therapeutic areas in which prescription digital therapeutics (PDTs) have been studied and show the most promise, as well as some of the unmet needs in patients with mental health conditions that PDTs may be able to address.

Arwen Podesta, MD, details the benefit and safety of prescription digital therapeutics.

Arwen Podesta, MD, examines the role of photodynamic therapies in integrative care and assess how they impact patient outcomes.

Experts discuss the importance of effective patient communication regarding prescription digital therapeutics (PDTs), the need for clinician training prior to PDT implementation, and key considerations for healthcare providers when prescribing these digital interventions.

Arwen Podesta, MD, discusses key factors for the successful implementation of prescription digital therapeutics (PDTs) in clinical settings and how PDT manufacturers can support this process.

A medical expert discussses examples of successful prescription digital therapeutic (PDT) implementations and their impact on patient care, managed care coverage challenges related to PDTs, strategies to improve patient access, and methods for evaluating patient outcomes and satisfaction with PDTs.

Dr. Podesta discuss the managed care coverage challenges related to PDTs and explore strategies for improving patient access, while also addressing methods for evaluating patient outcomes and satisfaction with PDTs.